Larimar Therapeutics (LRMR) Income towards Parent Company: 2014-2020
Historic Income towards Parent Company for Larimar Therapeutics (LRMR) over the last 6 years, with Mar 2020 value amounting to -$3.6 million.
- Larimar Therapeutics' Income towards Parent Company rose 72.55% to -$3.6 million in Q1 2020 from the same period last year, while for Mar 2020 it was -$35.9 million, marking a year-over-year increase of 38.50%. This contributed to the annual value of -$45.4 million for FY2019, which is 25.68% up from last year.
- According to the latest figures from Q1 2020, Larimar Therapeutics' Income towards Parent Company is -$3.6 million, which was up 50.66% from -$7.3 million recorded in Q4 2019.
- In the past 5 years, Larimar Therapeutics' Income towards Parent Company registered a high of -$3.6 million during Q1 2020, and its lowest value of -$17.8 million during Q1 2016.
- Moreover, its 3-year median value for Income towards Parent Company was -$13.1 million (2019), whereas its average is -$12.2 million.
- In the last 5 years, Larimar Therapeutics' Income towards Parent Company crashed by 32.76% in 2016 and then surged by 72.55% in 2020.
- Quarterly analysis of 5 years shows Larimar Therapeutics' Income towards Parent Company stood at -$10.3 million in 2016, then declined by 26.76% to -$13.1 million in 2017, then declined by 10.72% to -$14.5 million in 2018, then skyrocketed by 49.65% to -$7.3 million in 2019, then spiked by 72.55% to -$3.6 million in 2020.
- Its Income towards Parent Company was -$3.6 million in Q1 2020, compared to -$7.3 million in Q4 2019 and -$12.9 million in Q3 2019.